

**Identification and pathological characterization of persistent asymptomatic Ebola  
virus infection in rhesus monkeys**

Xiankun Zeng<sup>1\*</sup>, Candace D. Blancett<sup>1</sup>, Keith A. Koistinen<sup>1</sup>, Christopher W. Schellhase<sup>1</sup>,  
Jeremy J. Bearss<sup>1</sup>, Sheli R. Radoshitzky<sup>1</sup>, Shelley P. Honnold<sup>1</sup>, Taylor B. Chance<sup>1</sup>, Travis  
K. Warren<sup>1</sup>, Jeffrey W. Froude<sup>1</sup>, Kathleen A. Cashman<sup>1</sup>, John M. Dye<sup>1</sup>, Sina Bavari<sup>1</sup>,  
Gustavo Palacios<sup>1</sup>, Jens H. Kuhn<sup>2</sup>, Mei G. Sun<sup>1</sup>

<sup>1</sup>United States Army Medical Research Institute of Infectious Diseases, 1425 Porter  
Street, Fort Detrick, Frederick, Maryland 21702, USA; <sup>2</sup>Integrated Research Facility at  
Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of  
Health, B-8200 Research Plaza, Frederick, Maryland 21702, USA

\*email: [xiankun.zeng.fn@mail.mil](mailto:xiankun.zeng.fn@mail.mil)

**Abstract**

Ebola virus (EBOV) persistence in asymptomatic humans and Ebola virus disease (EVD)  
sequelae have emerged as significant public health concerns since the 2013–2016 EVD  
outbreak in Western Africa. Until now, studying how EBOV disseminates into and  
persists in immune-privileged sites was impossible due to the absence of a suitable  
animal model. Here we detect persistent EBOV replication with possibly coinciding  
systematic inflammatory responses in otherwise asymptomatic rhesus monkeys that had  
survived infection in the absence of or after treatment with candidate medical  
countermeasures. We document progressive EBOV dissemination into eyes, brain, and

testes through vascular structures similar to observations in humans. We identify CD68<sup>+</sup> cells (macrophages/monocytes) as the cryptic EBOV reservoir cells in the vitreous humor and its immediately adjacent tissue, in the tubular lumina of the epididymides, and in foci of apparently histiocytic inflammation in the brain but not in organs typically affected during acute infection. In conclusion, our data suggest that human persistent EBOV infection could be modelled in rhesus monkeys, and demonstrate that promising candidate medical countermeasures may not completely clear EBOV infection. A rhesus monkey model may lay the foundation to study EVD sequelae and to develop therapies to abolish EBOV persistence.

## Introduction

Ebola virus disease (EVD) is a severe human viral hemorrhagic fever caused by infection with either Bundibugyo virus (BDBV), Ebola virus (EBOV), Sudan virus (SUDV), or Tai Forest virus (TAFV).

From 2013 to 2016, an EBOV-caused EVD outbreak in Western Africa led to a total of 28,646 cases and 11,323 deaths worldwide (case-fatality rate of 40%)<sup>1</sup>. The large number of EVD survivors revealed previously underestimated sequelae of EBOV infection or “post-Ebola (virus disease) syndrome.” This syndrome includes arthralgia, cognitive impairment, headaches, hearing loss, and myalgia<sup>2-5</sup>. About 50% of surveyed survivors of this outbreak complained of various ocular complications such as blurry vision, pain, and discomfort. One fifth of these survivors were diagnosed with uveitis<sup>3,6-12</sup>. In one uveitis case, EBOV was isolated from the eye<sup>11</sup>. Another EVD survivor developed

meningoencephalitis more than 9 months after convalescence, and EBOV could be isolated from the patient's cerebrospinal fluid<sup>8</sup>.

EBOV RNA was detected in seminal fluid of survivors up to 18 months after the onset of symptoms<sup>7,9,10,12,13</sup>, and in one case, EBOV was successfully isolated from seminal fluid at least several weeks after convalescence<sup>12</sup>. Most importantly, male-to-female sexual transmission from two persistently EBOV-infected EVD survivors, 6 and 15 months after convalescence, respectively, was confirmed by genetic sequence comparison of EBOV in the blood of virus donors and recipients<sup>13-15</sup>. One of these transmissions became the epidemiological basis for a new cluster of EVD cases<sup>13</sup>. Several other EVD transmission chains are likely to have originated from the reintroduction of EBOV from a persistently infected source<sup>16-18</sup>.

Together, these reports indicate the need for a high priority effort to understand EBOV persistence and relapse *in vivo*. Persistent EBOV might not only threaten the long-term survival of immediate EVD survivors, but also can be transmitted and start novel flare-ups. However, until now, no animal model for EBOV persistence and relapse has been developed, and the molecular pathology of persistent EBOV infection in immune-privileged sites has not been examined. Here we report for the first time persistent EBOV infection in eyes, epididymides, and brain tissues of experimentally EBOV-infected rhesus monkey survivors. We illustrate the anatomical location and cellular targets of EBOV in these tissues. We demonstrate that EBOV spreads into specific locations at immune-privileged sites through vascular structures. In addition, we provide evidence that EBOV persistence is associated with ongoing replication in the likely presence of an inflammatory host response.

69

## 70 **Results**

71 **Ebola virus persists in rhesus monkey survivors.** Nonhuman primates (NHPs), in  
72 particular macaques, are broadly used as experimental animal models of EVD<sup>19</sup>. Yet, to  
73 our knowledge, persistent EBOV infection has not been reported in NHP survivors of  
74 experimental infection. Using *in situ* hybridization (ISH), we screened a collection of  
75 archived tissue (eye, testicle, brain, lymph node, liver, spleen) samples from 112 rhesus  
76 monkeys that had survived experimental EBOV infection through day 43 post-exposure.  
77 Only a portion of survivors, 11 of 112 (9.82%), had detectable EBOV genomic RNA in  
78 eye, testicle, or brain tissues. Specifically, 9 of 78 tested eyes (11.54%), 1 of 76 testes  
79 (1.32%) and 1 of 80 brains (1.25%) contained EBOV genomic RNA. In contrast, EBOV  
80 genomic RNA was undetectable in the common acute EBOV infection target tissues  
81 (liver, lymph node, and spleen). Next to rhesus monkeys, crab-eating macaques are  
82 frequently used for experimental EBOV infections<sup>19</sup>. We therefore also screened a  
83 collection of archived tissues samples from 48 crab-eating macaques that had survived  
84 EBOV infection. Importantly, the rhesus monkey tissues were derived from animals that  
85 either received non-vaccine MCMs or were untreated, whereas the only tissues from  
86 crab-eating macaques available for this study originated from animals that had received  
87 candidate vaccines. There was no evidence of EBOV persistence in the examined crab-  
88 eating macaque eye, testis, and brain tissues using ISH (data not shown).

89 Tissues from 8 of the 11 rhesus monkey survivors that tested positive for EBOV  
90 both by ISH and immunofluorescence were more closely examined (Supplementary  
91 Table 1). Of note, 2 of the 8 (25%) natural survivors that had not been treated with

candidate medical countermeasures (MCMs) were found to be persistently infected with EBOV (Survivor 1 and Survivor 5).

**Ebola virus persistently infects the vitreous humor and its adjacent structures.**

Genomic EBOV RNA was detected in the ocular tissue (vitreous humor and its adjacent structures were predominant) of 6 of 8 rhesus monkeys by ISH using EBOV genomic nucleoprotein (NP) gene-specific probes (Fig. 1). In contrast, genomic EBOV RNA could not be detected in brains, livers, lymph nodes, ovaries/uteri, spleens, or prostates/testicles from these animals (Supplementary Table 1).

**Ebola virus spreads into sites of persistence through blood vessels in the eye.**

Intramuscular infection of rhesus monkeys with 1,000 pfu of EBOV generally results in 100% fatality with death occurring 5–11 days after exposure<sup>20-22</sup>, here called “acute course of disease death” (ACDD). Previous studies revealed the presence of EBOV antigen in the scleras, corneal epithelia, retinas, and optic nerve leptomeninges of EBOV-infected rhesus monkeys that perished prior to the study endpoint but survived longer than ACDD (i.e., 16–24 days post-exposure, here referred to as “delayed time of death [DTOD]”)<sup>21,23</sup>. We further analyzed sections of eyes from 24 rhesus monkeys with ACDD (Supplementary Table 2) and 14 rhesus monkeys with DTOD using ISH (Supplementary Table 3). Strikingly, in animals with ACDD, EBOV genomic RNA was not detected in the parenchymal eye tissues (Fig. 1f), but was consistently detected in blood vessels of the choroids (17 of 24, 70.83 %; Supplementary Fig. 1a), ciliary processes (18 of 24, 75%; Supplementary Fig. 1b) and/or in the optic nerve

leptomeninges (6 of 24, 25%; Supplementary Fig. 1c). Consistently, EBOV glycoprotein (GP)<sub>1,2</sub> antigen was specifically detected within CD31 antibody-labeled blood vessels by immunofluorescence staining (Supplementary Fig. 1d-d").

Among animals with DTOD (Fig. 1g), EBOV genomic RNA was predominantly detected in the optic nerve leptomeninges (12 of 14, 85.71%; Supplementary Fig. 1e), scleral connective tissues (7 of 14, 50%; Supplementary Fig. 1f), cilia and irises (3 of 14, 21.43%; Supplementary Fig. 1g), and choroids (2 of 14, 14.29%; Supplementary Fig. 1h). Interestingly, in 1 infected animal with DTOD, EBOV genomic RNA was present in cells in the vitreous humor in addition to optic nerve leptomeninges, and scleras (1 of 14, 7.14%; Supplementary Fig. 1i-i').

Persistent EBOV infection in survivors was confined to the inner vitreous humor and immediately adjacent structures (Fig. 1h). These data suggest the possibility that ocular EBOV infection originates from EBOV in blood vessels of the choroid and cilia, or optic nerve leptomeninges with subsequent spread to adjacent structures. The infection of outer scleral and uveal layers and optic nerve leptomeninges may be cleared after recovery while EBOV persists in the inner vitreous humor and its adjacent structures.

**CD68<sup>+</sup> cells are cellular targets of Ebola virus persistence in the eye.** We examined survivor eye sections using immunofluorescence staining with anti-EBOV GP<sub>1,2</sub> antibodies to determine whether EBOV RNA-positive tissues actually contain EBOV GP<sub>1,2</sub> antigen. EBOV GP<sub>1,2</sub> antigen was detectable in the same group of infected cells from survivors that tested positive by ISH (Fig. 2a-b). Dendritic cells (DCs) and macrophages are believed to be primary targets of acute EBOV infection in primates<sup>24,25</sup>.

Hematoxylin and eosin (H&E) staining suggested numerous inflammatory cells, including cells that had the morphologic appearance of macrophages, in the vitreous humor and the retinal inner limiting membranes of survivors (Fig. 2c-d). To identify the cellular targets of persistent EBOV infection, we stained survivor eye sections by immunofluorescence using anti-EBOV GP<sub>1,2</sub> antibody and antibody against a macrophage/monocyte marker, CD68. Most cells that tested positive for EBOV GP<sub>1,2</sub> antigen were also labeled by the anti-CD68 antibody (Fig. 2e-h').

**Uveitis, retinitis, and vitritis are accompanied by reactive gliosis with Ebola virus persistence.** Six of 8 survivors indeed revealed moderate-to-severe uveitis. Infiltration of cells, including macrophages, was found within the ciliary bodies, irises, and scleras near the corneoirideal angles (Fig. 3a-b, Supplementary Fig. 2a-d). Infiltration occasionally extended along cyclitic membranes. CD68 staining suggested that some of the uvea-infiltrating cells were macrophages or monocytes (Supplementary Fig. 2e).

Retinitis occurred in 4 survivors, typically characterized by perivascular accumulation of likely inflammatory cells (Fig. 3c-d, Supplementary Fig. 2g-h). CD68<sup>+</sup> cell infiltration of the retinas was commonly observed (Fig. 3e-f). Infiltrating cells, including CD68<sup>+</sup> cells, and/or neutrophils, were also found in the vitreous humor adjacent to the cilia and retinas of the 4 survivors (vitritis, Fig. 3b-c, g-h, Supplementary Fig. 2f-h).

Using an antibody against glial fibrillary acidic protein (GFAP) to outline retinal structures of the six survivors, we unexpectedly found dramatically upregulated GFAP immunoreactivity in Müller cell processes that extended into the inner and outer nuclear

layers (Fig. 3j–l, Supplementary Fig. 2i–j). In contrast, very limited GFAP immunoreactivity was observed in the ganglion cell layer of a normal eye of an uninfected control monkey (Fig. 3i). Both upregulation of GFAP and cell proliferation are hallmarks of reactive gliosis subsequent to acute retinal injury or chronic neuronal stress<sup>26,27</sup>. Some retinal cells were labeled with the cell proliferation marker Ki67 (Fig. 3m–p), suggesting that cell proliferation was activated to maintain retinal homeostasis during EBOV persistence.

**Ebola virus persistence in the brain of a rhesus monkey survivor.** Persistence and relapse of EBOV in the central nervous system in an EVD survivor have been reported<sup>8</sup>. However, how EBOV is able to bypass the blood-brain barrier to access immune-privileged sites and which cells are being targeted by EBOV to establish persistence in the brain remain unknown. We identified 1 of 8 rhesus monkey survivors that survived to the end of study (28–43 days) on day 36 and tested positive for EBOV RNA in the corpus striatum of the brain (Supplementary Table 1). EBOV RNA was specifically detected in foci of histiocytic encephalitis (glial nodules) in which we detected activated microglia (Fig. 4a and Supplementary Fig. 3a). Additional evidence of encephalitis included intense perivascular infiltration of mononuclear cells that filled the Virchow-Robbins space in the corpus striatum of the brain (Supplementary Fig. 3b, c).

Immunofluorescence staining revealed most of the cells in the glial nodule to be CD68<sup>+</sup> cells, some of which were associated with EBOV GP<sub>1,2</sub> antigen (Fig. 4b–b’’). Interestingly, EBOV genomic RNA was absent from parenchymal brain tissues but was consistently detected in endothelial cells of blood vessels of animals with ACDD (19 of

24, 79.16%; Fig. 4c, Supplementary Table 2). However, in animals with DTOD, EBOV genomic RNA was mainly found in foci of histiocytic encephalitis most often associated with perivascular glial nodules (14 of 15, 93.33%; Fig. 4d, (Supplementary Table 3). EBOV GP<sub>1,2</sub> antigen was specifically located in CD31 antibody-labeled vascular (Fig. 4e–e') endothelial cells of the blood brain barrier in animals with ACDD. Additionally, some of the blood endothelial cells infected by EBOV e underwent apoptosis (Fig. 4f). In contrast, GP<sub>1,2</sub> antigen was mainly detected in CD68 antibody-labeled microglial clusters, which were predominantly observed in the vicinity of CD31 antibody-labeled blood vessels in the brains of animals with DTOD (Fig. 4g–i). Our observations suggest that initial EBOV infection of the vascular endothelium in the brain may lead to breakdown of the blood-brain barrier and may result in subsequent histiocytic inflammation and perivascular EBOV infection in microglia. EBOV may replicate and persist in these inflammatory microglial cells after recovery (Fig. 4j).

**Ebola virus persistence in the epididymis of a rhesus monkey survivor.** We identified 1 of 8 rhesus monkey survivors, euthanized on day 43, with EBOV persistence in testicular tissue using ISH (Supplemental Table 1 and Fig. 5a–a'). Strikingly, EBOV RNA was only found in the tubular lumen of one epididymis but not in the testes. The tubular lumen of this immature animal was congested by cells, including CD68<sup>+</sup> cells, and necrotic cellular debris, composed of degenerate neutrophils, macrophages, and spermatogonia (Fig. 5b). EBOV GP<sub>1,2</sub> antigen was detected in some CD68<sup>+</sup> cells or extracellularly within the tubular lumen of the epididymis (Fig. 5c–c'). In addition,

inflammatory cells, including macrophages, eosinophils, and lymphocytes, were found in interstitial connective tissue (Fig. 5b), suggesting epididymitis.

To further evaluate EBOV persistence in the testes and epididymides, we screened testicular tissues from 24 rhesus monkeys with ACDD (Supplementary Table 2) and 8 rhesus monkeys with DTOD (Supplementary Table 3). Twenty two of 24 (91.67%) animals with ACDD had detectable EBOV genomic RNA mostly in the vascular structure including in endothelial cells (Fig. 5d–d') in both testes and epididymides.

Immunofluorescence staining illustrated that EBOV was detected mainly in vascular structures including blood vessels labeled by CD31 antibody and CD31-negative lymphatic vessels (Fig. 5e–e'). In contrast, 5 of 8 (62.5%) animals with DTOD had broad detectable EBOV genomic RNA in the interstitia of testes and/or epididymides (Fig. 5f–f'). Consistently, immunofluorescence showed wide EBOV antigen distribution in interstitia (Fig. 5g). EBOV genomic RNA was also found in the seminiferous tubules in 2 of those 5 animals with DTOD but not in any of the animals with ACDD (Fig. 5h–h'). EBOV GP1,2 antigen was detected in germ cells in seminiferous tubules labeled by DDX4/Vasa antibody (Fig. 5i–i"). Consistently, it has been reported that EBOV was detected in seminiferous tubules in addition to interstitial infection in a fatal human case of Ebola virus infection<sup>28</sup>.

**Ebola virus replicates in immune-privileged sites.** Our study was based on archived fixed tissues and live titration of EBOV could therefore not be performed. Thus, to determine whether EBOV actively replicates in immune-privileged sites associated with persistence, we developed a multiplex fluorescence *in situ* hybridization (FISH) assay

that differentiates between genomic and antigenomic EBOV RNA in tissues. Surprisingly, we detected not only the EBOV genome, but also the EBOV antigenome, in the eye, epididymis, and brain tissues of survivors, suggesting ongoing EBOV replication at the time of euthanasia (Fig. 6a–f'''). Interestingly, EBOV replicated at a lower level in the eyes of two survivors compared to that observed in two others (Fig. 6a–d''' and g). This higher level of viral replication coincided with more severe inflammation-like responses in the eyes.

## Discussion

EBOV persistence and post-EVD syndrome have become significant public health concerns amid reports of sexual EBOV transmission and EVD outbreak flare-ups originating from persistently infected survivors since the 2013–2016 EVD outbreak in Western Africa. Our data suggest that EBOV may progressively disseminate into eyes, brain, and testes through vascular structures, and likely persists in CD68<sup>+</sup> (macrophage/monocyte) cells in rhesus monkey survivors of EBOV infection. We observed a likely inflammatory host immune response in immune-privileged tissues possibly due to active viral replication. In NHPs, acute EBOV infection primarily affects areas connected directly or adjacent to blood vessels with replication mainly occurring in the liver, kidney, lung, and lymphatic organs with possible later transition to infection of blood vessel-adjacent structures in the brain, eyes, and testes. After that, EBOV eventually spreads to sites of persistence from which the virus cannot be cleared. The animals here called survivors would still have been at risk of “relapse.” However, as

251 rhesus monkey survivors of EBOV infection typically are not maintained beyond  $\approx 40$   
252 days after initial EBOV exposure, the possibility of relapse could not be assessed.

253       The large and unprecedented 2013–2016 EVD outbreak in Western Africa  
254 highlighted diverse clinical sequelae of EVD in thousands of survivors<sup>2-5</sup>. While the  
255 molecular etiology of these sequelae is unclear, EBOV persistence accompanied by local  
256 inflammatory reactions in apparently healthy survivors could at least partially explain the  
257 persistence of pain at various body sites and/or visual, acoustic, and cognitive  
258 impairments. Indeed, EBOV persistence in the eyes, testicles, and brains of a few human  
259 survivors, substantiated by virus isolation<sup>8,11,12,29</sup>, possibly caused frequently reported  
260 EVD sequelae such as vision loss, orchitis, and confusion, respectively. In at least once  
261 case, EBOV persistence led to repeated disease recurrence in a survivor several weeks  
262 after clinical recovery<sup>8</sup>, suggesting that survivors should not necessarily be considered  
263 completely cleared of the virus. Future studies aimed at understanding the molecular  
264 basis of EBOV persistence could include genomic characterization of EBOV in infected  
265 cells at immune-privileged sites compared to actively circulating EBOV in acute disease.  
266 Genomic sequencing of tissue-specific EBOV populations may help explain the  
267 extraordinarily low mutation rate of EBOV associated with persistence in humans<sup>16,30</sup>.

268       Several instances of new EVD case clusters were linked directly to persistently  
269 EBOV-infected, apparently healthy survivors of the 2013–2016 EVD outbreak<sup>13-17</sup>.  
270 Although rare, such transmissions could prove to be catastrophic. The majority of EVD  
271 outbreaks could be traced back to single virus introductions from a natural reservoir into  
272 the human population, with subsequent person-to-person transmission<sup>31</sup>. In the 2013–  
273 2016 EVD outbreak, specifically, a single EBOV introduction ultimately led to 28,646

human infections<sup>16,32</sup>. Understanding the molecular-virological mechanism of EBOV persistence is of paramount importance, including the conditions that favor persistence and reactivation and the time frame in which they may occur. Ultimately, the goal must be the development of MCMs that prevent or abolish EBOV persistence in survivors.

Currently, no established animal models of persistent EBOV infection are available. All frequently used animal models for EVD typically result in 100% fatality<sup>33</sup>. Our study clarifies that a robust rhesus monkey model for EBOV persistence could be developed based on partial clearance of EBOV from experimentally infected animals and used to evaluate various candidate MCMs. Additionally, two natural rhesus monkey survivors with persistent EBOV reported here had not been treated with MCMs, which suggests that a robust rhesus monkey model of EBOV persistence might be developed by increasing the survival rate of infected macaques. We found persistent EBOV in three key immune-privileged sites (i.e., eyes, testicles, brains) only in rhesus monkeys, but not in crab-eating monkeys. However, all the crab-eating monkeys examined in this study had been exposed to EBOV after receiving candidate vaccinations, whereas all the examined rhesus monkey survivors had been treated with experimental MCMs post-EBOV exposure or had not been treated at all. Vaccine-related EBOV suppression possibly prevented EBOV dissemination to and replication in immune-privileged sites. Consequently, our findings in rhesus monkeys and crab-eating macaques ought not to be compared directly. Instead, follow-up studies should investigate whether crab-eating macaques that survived EBOV infection after treatment with non-vaccine MCMs also develop persistent EBOV infections. In addition, follow-up studies ought to clarify

whether our observations regarding EBOV persistence in brain and testis tissues, both based on single animals, can be generalized.

## Methods

**Tissues.** Formalin-fixed paraffin-embedded (FFPE) brain, eye, testis, and epididymis tissues of rhesus monkeys (*Macaca mulatta*) or crab-eating (aka cynomolgus) monkeys (*Macaca fascicularis*) that had been experimentally infected with Ebola virus/H.sapiens-tc/COD/1995/Kikwit-9510621 (EBOV) were retrieved from the US Army Medical Research Institute of Infectious Diseases (USAMRIID) Pathology Division tissue archives. For the purpose of this manuscript, “survivor” refers to monkeys that survived EBOV infection after exposure until study endpoints (28–43 days after EBOV exposure) with or without treatment with distinct MCMs, including cocktails of monoclonal antibodies (mAbs), small interfering RNAs (siRNAs), antisense phosphorodiamidate morpholino oligomers (PMOs), or vaccination with Venezuelan equine encephalitis virus replicon particles expressing EBOV GP<sub>1,2</sub> (VRP-GP). For the purposes of comparing the type of cells and anatomical sites infected during acute and persistent infection, we also collected the same tissues from rhesus monkeys that did not survive EBOV exposure. For analysis, we further divided this group into animals that died within the typical post-exposure time frame [5–11 days post-exposure, here referred as “acute course of disease death (ACDD)” in this study] and animals that perished prior to the study endpoint but survived longer than the typical post-exposure time frame [usually 16–24 days post-exposure, here referred as “delayed time of death (DTOD)” in this study]. Sections were

stained with hematoxylin and eosin (H&E) after deparaffinization. Sections of different tissues from uninfected rhesus monkeys were used as controls.

**RNA *in situ* hybridization.** EBOV has a linear, single-stranded, negative-sense non-segmented RNA genome ( $\approx 19$  kb) that encodes seven structural proteins<sup>35</sup>. EBOV genome replication involves synthesis of the (positive-sense) RNA antigenome, which in turn serves as a template to generate progeny (negative-sense) genomes; and synthesis of (positive-sense) mRNAs from individual genes that are translated into structural proteins<sup>36</sup>. To detect EBOV RNA in FFPE tissues, *in situ* hybridization (ISH) was performed using the RNAscope® 2.5 HD RED kit<sup>37</sup> (Advanced Cell Diagnostics, Newark, CA) according to the manufacturer's instructions. Briefly, 20 ZZ probe pairs targeting the genomic EBOV NP gene were designed and synthesized by Advanced Cell Diagnostics (Cat# 448581). After deparaffinization with xylene, a series of ethanol washes, and peroxidase blocking, sections were heated in antigen retrieval buffer and then digested by proteinase. Sections were exposed to ISH target probe and incubated at 40°C in a hybridization oven for 2 h. After rinsing, ISH signal was amplified using company-provided Pre-amplifier and Amplifier conjugated to horseradish peroxidase (HRP), and incubated with a red substrate-chromogen solution for 10 min at room temperature. Sections were then stained with hematoxylin, air-dried, and mounted.

**Multiplex fluorescence *in situ* hybridization.** Multiplex fluorescence *in situ* hybridization (FISH) was performed using the RNAscope® Fluorescent Multiplex Kit (Advanced Cell Diagnostics) according to the manufacturer's instructions with minor

modifications. Twenty ZZ probe pairs with C1 channel (red, Cat# 448581) targeting EBOV genomic *NP* gene and 20 ZZ probe pairs with C3 Channel (Cat# 451691), green) targeting the EBOV antigenomic *VP35* gene were synthesized by Advanced Cell Diagnostics. FFPE-tissue sections underwent deparaffinization with xylene and a series of ethanol washes. These tissue sections were treated with 0.1% Sudan Black B (Sigma-Aldrich, St. Louis, MO, USA) to reduce autofluorescence, heated in antigen retrieval buffer, and digested by proteinase. Sections were exposed to ISH target probes and incubated at 40°C in a hybridization oven for 2 h. After rinsing, ISH signal was amplified using company-provided Pre-amplifier and Amplifier conjugated to fluorescent dye. Sections were counterstained with 4',6-diamidino-2-phenylindole (DAPI, Thermo Fisher Scientific, Waltham, MA, USA), mounted, and stored at 4°C until image analysis. FISH images were captured on an LSM 780 Confocal Microscope (Zeiss, Oberkochen, Germany) and processed using open-source ImageJ software (National Institutes of Health, Bethesda, MD, USA).

**Immunofluorescence staining.** After deparaffinization and treatment with 0.1% Sudan Black B to reduce autofluorescence, tissues were heated in citrate buffer (Sigma-Aldrich), pH 6.0, for 15 min to reverse formaldehyde cross-links. After rinses with phosphate-buffered saline, pH 7.4 (PBS, Thermo Fisher Scientific), sections were blocked overnight with PBS containing 5% normal goat serum (Sigma-Aldrich) at 4°C. Sections were then incubated with primary antibodies (USAMRIID rabbit polyclonal antibody against EBOV GP<sub>1,2</sub> at a dilution of 1:2,000; mouse anti-human CD68 antibody at a dilution of 1:200 [Clone KP1, Dako Agilent Pathology Solutions, Carpinteria, CA,

364 USA]; rabbit polyclonal antibody against glial fibrillary acidic protein [GFAP] at a  
365 dilution of 1:100 [ab7260, Abcam; Cambridge, MA, USA]; rabbit polyclonal antibody  
366 against Ki67 [ab15580, Abcam] at a dilution of 1:400; rabbit polyclonal antibody against  
367 DDX4/Vasa [ab13840, Abcam] at a dilution of 1:100; rabbit polyclonal antibody against  
368 CD31 at a dilution of 1:100 [ab28364, Abcam; Cambridge, MA, USA]; rabbit  
369 monoclonal antibody against Cleaved Caspase-3 at a dilution of 1:100 [9664, Cell  
370 Signaling; Danvers, MA, USA]; USAMRIID mouse IgG2A anti-EBOV GP<sub>1,2</sub>  
371 monoclonal 6D8-1-2<sup>38</sup> at a dilution of 1:400) for 2 h at room temperature. After rinsing in  
372 PBS, sections were incubated with secondary goat IgG Alexa Fluor 488-conjugated anti-  
373 rabbit or anti-mouse and goat IgG Alexa Fluor 561-conjugated anti-mouse or anti-rabbit  
374 antibodies (Life Technologies, Carlsbad, CA) for 1 h at room temperature. Sections were  
375 cover-slipped using VECTASHIELD Antifade Mounting Medium with DAPI (Vector  
376 Laboratories, Burlingame, CA, USA). Images were captured and processed as describe  
377 above.

## References

1. World Health Organization. Ebola situation report – 30 March 2016.  
<http://apps.who.int/ebola/current-situation/ebola-situation-report-30-march-2016>.  
(2016).
2. Burki, T.K. Post-Ebola syndrome. *Lancet Infect Dis* **16**, 780-781 (2016).
3. Epstein, L., Wong, K.K., Kallen, A.J. & Uyeki, T.M. Post-Ebola signs and symptoms in U.S. survivors. *N Engl J Med* **373**, 2484-2486 (2015).
4. Scott, J.T., *et al.* Post-Ebola syndrome, Sierra Leone. *Emerging infectious diseases* **22**, 641-646 (2016).
5. Carod-Artal, F.J. Post-Ebolavirus disease syndrome: what do we know? *Expert Rev Anti Infect Ther* **13**, 1185-1187 (2015).
6. Mattia, J.G., *et al.* Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. *Lancet Infect Dis* **16**, 331-338 (2016).
7. Deen, G.F., *et al.* Ebola RNA persistence in semen of Ebola virus disease survivors - preliminary report. *N Engl J Med* (2015).
8. Jacobs, M., *et al.* Late Ebola virus relapse causing meningoencephalitis: a case report. *Lancet* **388**, 498-503 (2016).
9. Soka, M.J., *et al.* Prevention of sexual transmission of Ebola in Liberia through a national semen testing and counselling programme for survivors: an analysis of Ebola virus RNA results and behavioural data. *The Lancet. Global health* **4**, e736-743 (2016).
10. Sow, M.S., *et al.* New Evidence of Long-lasting Persistence of Ebola Virus Genetic Material in Semen of Survivors. *J Infect Dis* (2016).

- 401 11. Varkey, J.B., *et al.* Persistence of Ebola Virus in Ocular Fluid during  
402 Convalescence. *N Engl J Med* **372**, 2423-2427 (2015).
- 403 12. Uyeki, T.M., *et al.* Ebola virus persistence in semen of male survivors. *Clin Infect*  
404 *Dis* **62**, 1552-1555 (2016).
- 405 13. Diallo, B., *et al.* Resurgence of Ebola virus disease in Guinea linked to a survivor  
406 with virus persistence in seminal fluid for more than 500 days. *Clinical infectious*  
407 *diseases : an official publication of the Infectious Diseases Society of America*  
408 (2016).
- 409 14. Christie, A., *et al.* Possible sexual transmission of Ebola virus - Liberia, 2015.  
410 *MMWR. Morbidity and mortality weekly report* **64**, 479-481 (2015).
- 411 15. Mate, S.E., *et al.* Molecular evidence of sexual transmission of Ebola virus. *N*  
412 *Engl J Med* **373**, 2448-2454 (2015).
- 413 16. Blackley, D.J., *et al.* Reduced evolutionary rate in reemerged Ebola virus  
414 transmission chains. *Sci Adv* **2**, e1600378 (2016).
- 415 17. Arias, A., *et al.* Rapid outbreak sequencing of Ebola virus in Sierra Leone  
416 identifies transmission chains linked to sporadic cases. *Virus Evolution* **2**, vew016  
417 (2016).
- 418 18. World Health Organization. Statement on the 9th meeting of the IHR Emergency  
419 Committee regarding the Ebola outbreak in West Africa.  
420 <http://www.who.int/mediacentre/news/statements/2016/end-of-ebola-pheic/en/>.  
421 (2016).

- 422 19. Shurtleff, A.C. & Bavari, S. Animal models for ebolavirus countermeasures  
423 discovery: what defines a useful model? *Expert Opin Drug Discov* **10**, 685-702  
424 (2015).
- 425 20. Geisbert, T.W., *et al.* Treatment of Ebola virus infection with a recombinant  
426 inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. *Lancet* **362**,  
427 1953-1958 (2003).
- 428 21. Larsen, T., *et al.* Pathologic findings associated with delayed death in nonhuman  
429 primates experimentally infected with Zaire Ebola virus. *J Infect Dis* **196 Suppl 2**,  
430 S323-328 (2007).
- 431 22. Warren, T.K., *et al.* Therapeutic efficacy of the small molecule GS-5734 against  
432 Ebola virus in rhesus monkeys. *Nature* **531**, 381-385 (2016).
- 433 23. Alves, D.A., *et al.* Necrotizing Scleritis, Conjunctivitis, and Other Pathologic  
434 Findings in the Left Eye and Brain of an Ebola Virus-Infected Rhesus Macaque  
435 (Macaca mulatta) With Apparent Recovery and a Delayed Time of Death. *J Infect*  
436 *Dis* **213**, 57-60 (2016).
- 437 24. Geisbert, T.W., *et al.* Pathogenesis of Ebola hemorrhagic fever in primate models:  
438 evidence that hemorrhage is not a direct effect of virus-induced cytolysis of  
439 endothelial cells. *Am J Pathol* **163**, 2371-2382 (2003).
- 440 25. Schnittler, H.-J. & Feldmann, H. Marburg and Ebola hemorrhagic fevers: does the  
441 primary course of infection depend on the accessibility of organ-specific  
442 macrophages? *Clin Infect Dis* **27**, 404-406 (1998).
- 443 26. MacLaren, R.E. Development and role of retinal glia in regeneration of ganglion  
444 cells following retinal injury. *Br J Ophthalmol* **80**, 458-464 (1996).

- 445 27. Dyer, M.A. & Cepko, C.L. Control of Muller glial cell proliferation and activation  
446 following retinal injury. *Nat Neurosci* **3**, 873-880 (2000).
- 447 28. Martines, R.B., Ng, D.L., Greer, P.W., Rollin, P.E. & Zaki, S.R. Tissue and  
448 cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. *J*  
449 *Pathol* **235**, 153-174 (2015).
- 450 29. Rodriguez, L.L., *et al.* Persistence and genetic stability of Ebola virus during the  
451 outbreak in Kikwit, Democratic Republic of the Congo, 1995. *J Infect Dis* **179**  
452 **Suppl 1**, S170-176 (1999).
- 453 30. Diallo, B., *et al.* Resurgence of Ebola virus disease in Guinea linked to a survivor  
454 with virus persistence in seminal fluid for more than 500 days. *Clin Infect Dis* **63**,  
455 1353-1356 (2016).
- 456 31. Kuhn, J.H. Ebolavirus and Marburgvirus Infections. in *Harrison's Principles of*  
457 *Internal Medicine*, Vol. 2 (eds. Kasper, D.L., *et al.*) 1323-1329 (McGraw-Hill  
458 Education, Columbus, Ohio, USA, 2015).
- 459 32. Carroll, M.W., *et al.* Temporal and spatial analysis of the 2014-2015 Ebola virus  
460 outbreak in West Africa. *Nature* **524**, 97-101 (2015).
- 461 33. Nakayama, E. & Saijo, M. Animal models for Ebola and Marburg virus  
462 infections. *Frontiers in microbiology* **4**, 267 (2013).
- 463 34. Uyeki, T.M., *et al.* Clinical Management of Ebola Virus Disease in the United  
464 States and Europe. *N Engl J Med* **374**, 636-646 (2016).
- 465 35. Sanchez, A., Kiley, M.P., Holloway, B.P. & Auperin, D.D. Sequence analysis of  
466 the Ebola virus genome: organization, genetic elements, and comparison with the  
467 genome of Marburg virus. *Virus Res* **29**, 215-240 (1993).

- 468 36. Mühlberger, E., Weik, M., Volchov, V.E., Klenk, H.-D. & Becker, S. Comparison  
469 of the transcription and replication strategies of Marburg virus and Ebola virus by  
470 using artificial replication systems. *J. Virol* **73**, 2333-2342 (1999).
- 471 37. Wang, F., *et al.* RNAscope: a novel *in situ* RNA analysis platform for formalin-  
472 fixed, paraffin-embedded tissues. *J Mol Diagn* **14**, 22-29 (2012).
- 473 38. Wilson, J.A., *et al.* Epitopes involved in antibody-mediated protection from Ebola  
474 virus. *Science* **287**, 1664-1666 (2000).
- 475

## Acknowledgements

We thank Dr. Stephen Lockett and Kimberly Peifley at the Optical Microscopy and Analysis laboratory, National Cancer Institute at Frederick (Fort Detrick, Frederick, MD, USA) for use of their confocal microscope. We thank Laura Bollinger and Jiro Wada (NIH/NIAID Integrated Research Facility at Fort Detrick, Frederick, MD, USA) for critically editing the manuscript and figure preparation, respectively. We thank William Discher and John Braun at USAMRIID (Fort Detrick, Frederick, MD, USA) for the diagram and Dr. Mark Kortepeter and Dr. Anthony Cardile for their critical reading of the manuscript.

Work at United States Army Medical Research Institute of Infectious Diseases was funded by The Joint Science and Technology Office for Chemical and Biological Defense (JSTO-CBD) of the Defense Threat Reduction Agency (DTRA) and the Medical Countermeasure Systems (MCS) of the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD). This work was supported in part through Battelle Memorial Institute's prime contract with the US National Institute of Allergy and Infectious Diseases (NIAID) under Contract No. HHSN272200700016I. A subcontractor to Battelle Memorial Institute who performed this work is: J.H.K., an employee of Tunnell Government Services, Inc.

The views and conclusions contained in this document are those of the authors and should not be interpreted as necessarily representing the official policies, either expressed or implied, of the US Department of the Army, the US Department of Defense, the US Department of Health and Human Services, or of the institutions and companies affiliated with the authors. In no event shall any of these entities have any responsibility

or liability for any use, misuse, inability to use, or reliance upon the information contained herein. The US departments do not endorse any products or commercial services mentioned in this publication.

All USAMRIID studies described in this manuscript involved protocols approved by the Institute Animal Care and Use Committee and were conducted under an IACUC approved protocol in compliance with the Animal Welfare Act, PHS Policy, and other Federal statutes and regulations relating to animals and experiments involving animals. The facility where this research was conducted is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, National Research Council, 2011.

### **Author contributions**

X.Z. conceived and designed the experiments. X.Z. and C.B.D performed the in situ hybridization. X.Z. performed the immunofluorescence staining and confocal imaging. K.A.K., C.W.S., J.J.B., S.P.H., and T.B.C. performed histopathology. T.K.W., J.W.F., K.A.C., J.M.D., and S.B. provided experimental materials. X.Z., S.R.R., G.P., and J.H.K. interpreted the data and wrote the manuscript. S.B. and M.G.S coordinated and oversaw the study.

### **Additional Information**

Supplementary information is available for this paper.

Reprints and permissions information is available at [www.nature.com/reprints](http://www.nature.com/reprints).


Correspondence and requests for materials should be addressed to X.Z.

522


523 **Competing interests**

524 The authors declare no competing financial interests.

525 **Figure 1**



**Figure 1 | Detection of genomic EBOV RNA in eyes of rhesus monkey survivors by *in situ* hybridization.** Genomic EBOV RNA (red) detected by *in situ* hybridization (ISH) using an EBOV NP gene-specific probe in hematoxylin-stained (blue) FFPE sections. Single prime figures **a'–e'** are insets of **a–e** at high magnification. **a–a'**, Representative images demonstrating genomic EBOV RNA in cells within vitreous humor. **a''**, Schematic of EBOV-infected regions (red stars) including cells in the vitreous humor and cells attached to the retinal inner limiting membrane. **b–b'**, Genomic EBOV RNA detected by ISH in a cluster of cells in vitreous humor. **b''**, Schematic of EBOV-infected regions (red stars) in vitreous humor. **c–c'**, Representative images demonstrating EBOV RNA in cells at the interface between vitreous humor and ciliary bodies. **c''**, Schematic of EBOV-infected regions (red stars) in vitreous humor and at the interface between vitreous humor and its adjacent structures, including ciliary body and retina. **d–d'**, Representative image demonstrating EBOV RNA in cells of the retinal inner limiting membrane adjacent to vitreous humor. **d''**, Schematic of EBOV-infected regions (red stars) in vitreous humor and the retinal inner limiting membrane. **e–e'**, Representative image demonstrating genomic EBOV RNA in cells at the retinal inner limiting membrane. **e''**, Schematic of EBOV-infected regions (red dots) in the retinal inner limiting membrane. **f–h**, Compare ocular EBOV infection pattern of survivors **h** to animals with ACDD **f** and animals with DTOD **g**.

546 **Figure 2**

547

548 **Figure 2 | Ocular macrophages of survivors express EBOV GP<sub>1,2</sub> antigen. a, EBOV**549 GP<sub>1,2</sub> antigen (red) staining in a cluster of likely inflammatory cells, including

550 macrophages adjacent to the inner limiting membrane of the retina (labeled using a glial

551 fibrillary acidic protein (GFAP) antibody, green). Blue 4',6-diamidino-2-phenylindole

552 (DAPI) stain identifies nuclei. **b, EBOV GP<sub>1,2</sub> antigen staining (red) in roughly the same**553 location detected by immunofluorescence. **c, Likely inflammatory cells (e.g.,**

554 macrophages) and necrotic debris in vitreous humor adjacent to the retinal inner limiting


555 membrane (H&E staining). **d, Likely inflammatory cells, including macrophages, in**556 vitreous humor adjacent to the inner limiting membrane. **e–e'''**, Immunofluorescence557 staining of a cross section of the retina showing EBOV GP<sub>1,2</sub> antigen (green) in CD68<sup>+</sup>

558 cells (monocytes/macrophages, red) attached to the retinal inner limiting membrane

559 (ILM). ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer. **f,**

560 EBOV GP<sub>1,2</sub> antigen (green) in CD68<sup>+</sup> cells (red, monocytes/macrophages) in the  
561 vitreous humor. **g**, EBOV GP<sub>1,2</sub> antigen (green) in CD68<sup>+</sup> cells (red,  
562 monocytes/macrophages) in the vitreous humor. (H–H') EBOV GP<sub>1,2</sub> antigen (green) in  
563 CD68<sup>+</sup> macrophages (red) in the vitreous humor. Blue, nuclear stain by DAPI.

**Figure 3**




**Figure 3 | Persistent EBOV infection causes uveitis, retinitis, and vitritis**

**accompanied by reactive gliosis. a–b, Uveitis (H&E).** Likely inflammatory cells (red arrows), primarily macrophages, in the ciliary body and iris **a** and ciliary body and vitreous humor **b**, red arrowhead. **c**, Perivascular cuffs (red arrows) in the ganglion cell layer of the retina and likely inflammatory cells (red arrowheads) on the vitreous side of the inner limiting membrane. **d**, Perivascular inflammation-like response (red arrow) in the retina. **e–f**, CD68<sup>+</sup> cell (red) infiltration in the ganglion cell layer of GFAP-labeled retina (green). **g–h**, Excessive CD68<sup>+</sup> cells (red) in the anterior vitreous humor. **i**, In a


574 healthy retina, GFAP staining (green) is limited to the ganglion cell layer (GCL) and  
575 absent from the inner nuclear layer (INL) and outer nuclear layer (ONL). **j–l**, GFAP  
576 staining (green) is dramatically increased in Müller cell apical processes that extend into  
577 the INL and ONL. **m–o**, Assessment of cell proliferation by Ki67 detection (green) in a  
578 healthy retina **m** and in retina of survivors **n–o**. **p**, Quantification of Ki67<sup>+</sup> cells in normal  
579 eye and eyes of survivors. Data are represented as mean  $\pm$  standard error of the mean,  
580 n=9, 5, 5.

581 **Figure 4**



582

**Figure 4 | Ebola virus persistence in the brain of a rhesus monkey survivor. a,**  
EBOV genomic RNA detection by ISH in a glial nodule in the corpus striatum of brain  
(the inset is the image with high magnification). **b–b''**, Immunofluorescence staining  
reveals EBOV GP<sub>1,2</sub> antigen (green) in CD68<sup>+</sup> microglia (red) or extracellularly within a  
glial nodule. Blue, nuclear stain by 4',6-diamidino-2-phenylindole (DAPI). **c**, Vascular  
EBOV genomic RNA in the brain of animals with acute course of disease death (ACDD).  
**d**, EBOV genomic RNA in the glial nodule in the brain of animals with delayed time of  
death (DTOD). **e–e'**, Immunofluorescence demonstrated EBOV GP<sub>1,2</sub> (green) in CD31  
antibody (red) labeled vascular endothelial cells in the brain of animals with ACDD. **f**,  
EBOV (green) infected endothelia cell was cleaved caspase-3 positive suggestive of  
ongoing apoptotic cell death. **g–i**, Immunofluorescence staining of three serial brain  
sections of animals with DTOD demonstrated that CD68 antibody-labeled (green in **f**)  
microglia, in which EBOV GP<sub>1,2</sub> (green in **g–h**) was detected, aggregates in the vicinity of  
CD31 antibody-labeled (red in **f–g**) blood vessel. **j**, EBOV infection pattern in the brain of  
animals with ACDD, animals with DTOD, and survivors.

598 **Figure 5**

599

600 **Figure 5 | EBOV persistently infects the epididymis of a rhesus monkey survivor. a**601 and magnified **a'**, EBOV genomic RNA detection by ISH in the tubular lumen of the602 epididymis (red arrows). **b**, Epididymitis in the same location. Likely inflammatory cells,


603 including macrophages, eosinophils, and lymphocytes, are located in the interstitial

604 connective tissue (red arrowhead). The tubular lumen (red arrows) is congested with

605 likely inflammatory cells and necrotic cellular debris composed of degenerate

606 neutrophils, macrophages, spermatogonia, and sloughed epithelium. **c–c'**,607 Immunofluorescence staining reveals EBOV GP<sub>1,2</sub> antigen (green) in CD68<sup>+</sup> cells608 (macrophage/monocyte, red) or extracellularly in the tubular lumen of the epididymis. **d–**

609 **d'**, Genomic EBOV RNA in the vascular structure in interstitial testicular tissue **d** and  
610 connective tissue surrounding the epididymal ducts **d'** of animals with acute course of  
611 disease death (ACDD). **e–e'**, EBOV GP<sub>1,2</sub> antigen (green) in vascular structure including  
612 CD31-positive blood vessel (red, arrowhead) and CD31-negative lymphatic vessels  
613 (arrow). **f–f'**, EBOV genomic RNA in most of interstitial tissues of testis **f** and in  
614 connective tissue surrounding the epididymal ducts **f'** in animals with delayed time of  
615 death (DTOD). **g–g'**, EBOV genomic RNA in seminiferous tubules **g** and in cells  
616 surrounding epididymal ducts **g'** in animals with DTOD. **h**, EBOV GP<sub>1,2</sub> antigen (green)  
617 in interstitial tissue of testis in animals with DTOD. **i–i''**, EBOV GP<sub>1,2</sub> antigen in  
618 seminiferous tubules, in which germ cells were labeled by DDX4/Vasa antibody.

619 **Figure 6**620 **Figure 6 | EBOV replicates in the eyes, epididymides, and brains of rhesus monkey**621 **survivors.** Multiplex fluorescence *in situ* hybridization (FISH) was used to detect EBOV622 genome (red) and antigenome/mRNA (green) in eyes **a–d'''**, tubular lumen of the623 epididymis **e–e'''**, and brain **f–f'''**. Blue, nuclear stain by 4',6-diamidino-2-phenylindole

625 (DAPI). **g**, Quantification of the FISH intensity ratio between EBOV antigenome/mRNA  
626 and genome signals.

627 **Supplementary Tables and Figures**

628 **Supplementary Table 1.** *In situ* hybridization (ISH) results obtained from eight rhesus monkey survivors of Ebola virus (EBOV)

629 infection

| Survivor | Sex | Euthanasia day | Countermeasure evaluated              | Result of Ebola virus <i>in situ</i> hybridization |        |            |          |           |       |       |        |          |          |
|----------|-----|----------------|---------------------------------------|----------------------------------------------------|--------|------------|----------|-----------|-------|-------|--------|----------|----------|
|          |     |                |                                       | Liver                                              | Spleen | Lymph node | Left eye | Right eye | Brain | Ovary | Uterus | Testicle | Prostate |
| 1        | M   | 28             | None                                  | Neg                                                | Neg    | Neg        | Neg      | Pos       | Neg   | /     | /      | Neg      | Neg      |
| 2        | M   | 28             | siRNA                                 | Neg                                                | Neg    | Neg        | Pos      | Pos       | Neg   | /     | /      | Neg      | Neg      |
| 3        | F   | 43             | siRNA                                 | Neg                                                | Neg    | Neg        | Pos      | Neg       | Neg   | Neg   | Neg    | /        | /        |
| 4        | M   | 41             | PMO                                   | Neg                                                | Neg    | Neg        | Neg      | Pos       | Neg   | /     | /      | Neg      | Neg      |
| 5        | F   | 28             | None                                  | Neg                                                | Neg    | Neg        | Neg      | Pos       | Neg   | Neg   | Neg    | /        | /        |
| 6        | F   | 36             | Post-exposure vaccination with VRP-GP | Neg                                                | Neg    | Neg        | Neg      | Pos       | Neg   | Neg   | Neg    | /        | /        |
| 7        | M   | 43             | siRNA                                 | Neg                                                | Neg    | Neg        | Neg      | Neg       | Neg   | /     | /      | Pos      | Neg      |
| 8        | F   | 36             | PMO                                   | Neg                                                | Neg    | Neg        | Neg      | Neg       | Pos   | Neg   | Neg    | /        | /        |

/, not tested; Neg, ISH-negative; Pos, ISH-positive; siRNA, small interfering RNA; PMO, phosphorodiamidate morpholino oligomer; VRP-GP, Venezuelan equine encephalitis replicon particles expressing EBOV glycoprotein.

630

**Supplementary Table 2.** *In situ* hybridization (ISH) results obtained using tissues from 24 rhesus monkeys with acute course of disease death (ACDD)

| Animals with ACDD | Sex | Time to death (days) | Results of Ebola virus <i>in situ</i> hybridization |        |          |
|-------------------|-----|----------------------|-----------------------------------------------------|--------|----------|
|                   |     |                      | Eye*                                                | Brain* | Testicle |
| 1                 | M   | 7                    | Pos                                                 | Pos    | Pos      |
| 2                 | M   | 10                   | Pos                                                 | Pos    | Pos      |
| 3                 | M   | 10                   | Pos                                                 | Pos    | Pos      |
| 4                 | M   | 8                    | Pos                                                 | Neg    | Pos      |
| 5                 | M   | 8                    | Pos                                                 | Pos    | Pos      |
| 6                 | M   | 9                    | Pos                                                 | Pos    | Pos      |
| 7                 | M   | 9                    | Pos                                                 | Neg    | Pos      |
| 8                 | M   | 9                    | Pos                                                 | Pos    | Pos      |
| 9                 | M   | 10                   | Neg                                                 | Neg    | Neg      |
| 10                | M   | 10                   | Neg                                                 | Neg    | Neg      |
| 11                | M   | 6                    | Pos                                                 | Pos    | Pos      |
| 12                | M   | 8                    | Pos                                                 | Pos    | Pos      |
| 13                | M   | 8                    | Pos                                                 | Pos    | Pos      |
| 14                | M   | 9                    | Pos                                                 | Pos    | Pos      |
| 15                | M   | 9                    | Pos                                                 | Pos    | Pos      |
| 16                | M   | 11                   | Pos                                                 | Pos    | Pos      |
| 17                | M   | 11                   | Pos                                                 | Neg    | Pos      |
| 18                | M   | 11                   | Pos                                                 | Pos    | Pos      |
| 19                | M   | 7                    | Neg                                                 | Pos    | Pos      |
| 20                | M   | 7                    | Pos                                                 | Pos    | Pos      |
| 21                | M   | 7                    | Pos                                                 | Pos    | Pos      |
| 22                | M   | 8                    | Pos                                                 | Pos    | Pos      |
| 23                | M   | 9                    | Pos                                                 | Pos    | Pos      |
| 24                | M   | 6                    | Pos                                                 | Pos    | Pos      |


M, Male; Pos, ISH-positive; Neg, ISH-negative;

\* EBOV RNA was only detected in blood vessel and/or in vascular endothelial cells but not in parenchymal tissue of eyes or brain

**Supplementary Table 3.** *In situ* hybridization (ISH) results obtained using tissues from 18 EBOV-infected rhesus monkeys with DTOD  
DTOD, delayed time of death; /, not tested; Neg, ISH-negative; Pos, ISH-positive; PMO,

| Animals with DTOD | Sex | Time to death (days) | Countermeasure evaluated                                 | Results of Ebola virus <i>in situ</i> hybridization |           |       |          |
|-------------------|-----|----------------------|----------------------------------------------------------|-----------------------------------------------------|-----------|-------|----------|
|                   |     |                      |                                                          | Left eye                                            | Right eye | Brain | Testicle |
| 1                 | F   | 17                   | Post-exposure vaccination with VRP expressing EBOV GP1,2 | Pos                                                 | Pos       | Pos   | /        |
| 2                 | M   | 16                   | PMO                                                      | Pos                                                 | Pos       | Neg   | Neg      |
| 3                 | M   | 24                   | siRNA                                                    | Pos                                                 | Pos       | Pos   | Neg      |
| 4                 | F   | 20                   | siRNA                                                    | Neg                                                 | Pos       | Pos   | /        |
| 5                 | M   | 18                   | None                                                     | Pos                                                 | Pos       | Pos   | /        |
| 6                 | F   | 22                   | PMO                                                      | Pos                                                 | Pos       | Pos   | /        |
| 7                 | F   | 17                   | None                                                     | Pos                                                 | Pos       | Pos   | /        |
| 8                 | F   | 20                   | siRNA                                                    | Pos                                                 | Pos       | Pos   | /        |
| 9                 | M   | 16                   | mAb                                                      | Pos                                                 | Pos       | Pos   | Neg      |
| 10                | F   | 21                   | siRNA                                                    | Pos                                                 | Pos       | Pos   | /        |
| 11                | F   | 19                   | None                                                     | Pos                                                 | Pos       | Pos   | /        |
| 12                | M   | 16                   | mAb                                                      | Pos                                                 | Pos       | Pos   | Pos      |
| 13                | F   | 19                   | PMO                                                      | Pos                                                 | Pos       | Pos   | /        |
| 14                | F   | 18                   | PMO                                                      | Pos                                                 | Pos       | Pos   | /        |
| 15                | M   | 18                   | Favipiravir                                              | /                                                   | /         | /     | Pos      |
| 16                | M   | 16                   | PMO                                                      | /                                                   | /         | Pos   | Pos      |
| 17                | M   | 16                   | PMO                                                      | /                                                   | /         | /     | Pos      |
| 18                | M   | 21                   | PMO                                                      | /                                                   | /         | /     | Pos      |

phosphorodiamidate morpholino oligomer; siRNA, small interfering RNA; VRP, Venezuelan equine encephalitis replicon particles


641 **Supplementary Fig. 1**

642

643 **Supplementary Figure 1 | Detection of EBOV in the eyes of non-survivors.** Genomic  
 644 EBOV RNA was detected by ISH using an EBOV NP gene-specific probe. **a**, Genomic  
 645 EBOV RNA in blood vessels of choroid in non-survivors. **b**, Genomic EBOV RNA in  
 646 ciliary process of non-survivors. **c**, EBOV genomic RNA in optic nerve leptomeninges of  
 647 animals with acute course of disease death (ACDD). **d–d''**, Immunofluorescence  
 648 demonstrated EBOV GP<sub>1,2</sub> (green) within CD31-antibody (red) labeled blood vessel in


649 choroids of animals with ACDD. **e**, Genomic EBOV RNA in fibrous connective tissue of  
650 the optic nerve leptomeninges of animals with DTOD. **f**, Genomic EBOV RNA in scleral  
651 connective tissues of animals with DTOD. **g**, Genomic EBOV RNA in cilia and irises of  
652 animals with DTOD. (H) Genomic EBOV RNA in choroids of animals with DTOD. **i-i'**,  
653 Genomic EBOV RNA staining in infiltrating cells in the anterior vitreous humor in  
654 addition to predominant infection in fibrous connective tissue of the optic nerve  
655 leptomeninges and scleras in animals with DTOD.

Supplementary Figure 2



Supplementary Figure 2 | Inflammation-like response in the eyes of rhesus monkeys with persistent EBOV infection. **a–b**, Uveitis in the ciliary bodies and irises of survivors (H&E). **c**, Uveitis in the corneal drainage angle (H&E). **d**, Uveitis in the

661 ciliary body and iris at the corneoirideal angle (H&E). **e**, Immunofluorescence stain  
662 reveals CD68<sup>+</sup> cell (macrophage/monocyte, red) infiltration in the ciliary body and iris. **f**,  
663 Immunofluorescence reveals most infiltrating cells to be CD68<sup>+</sup> cells  
664 (macrophage/monocyte, red) in the vitreous humor adjacent to the ciliary body. **g-h**,  
665 Perivascular inflammation-like response (red arrow) in the retina and likely inflammatory  
666 cells (red arrowheads) in the vitreous humor adjacent to the cell-limiting membrane  
667 (H&E). **i-j**, Glial fibrillary acidic protein (GFAP) immunoreactivity (green) was  
668 dramatically increased in Müller cell apical processes that extend into the inner nuclear  
669 layer (INL) and outer nuclear layer (ONL). Blue, nuclear stain by 4',6-diamidino-2-  
670 phenylindole (DAPI).

671 **Supplementary Figure 3**

672

673 **Supplementary Figure 3 | Encephalitis in a rhesus monkey survivor with persistent**674 **EBOV infection.** Encephalitis is evidenced by glial nodule **a-b** and perivascular cuffs **c**.

675 Activated microglia (red arrow) in glial nodule.

